Quantcast

New Treatment for Kidney Transplant Patients

July 28, 2011

(Ivanhoe Newswire) — A new treatment for hard-to-match kidney transplant patients is providing dramatic survival benefits. According to the study, hard-to-match transplant candidates who receive a new treatment designed to make their bodies more accepting of incompatible organs are twice as likely to survive eight years after transplant surgery as those who stay on dialysis for years waiting for compatible organs.

It’s estimated that there is more than 20,000 hard-to-match transplant candidates in the United States. Their immune systems will reject most kidneys because of antibodies circulating in their blood that react to proteins known as human leukocyte antigens (HLA). These proteins are found on most cells and are used by the immune system to recognize what is foreign to the body. With HLA-sensitized patients, the body has been exposed to foreign HLA in the past, either through pregnancy, blood transfusion or previous kidney transplant, and it immediately recognizes most donor organs as unfamiliar, causing rejection. Women make up a majority of these patients because of sensitization from pregnancy.

“Apart from the scarcity of donor kidneys, the biggest barrier to kidney transplant right now is the percentage, nearly one in three, of patients on the waiting list whose immune systems make them likely to reject most kidneys available to them,” Robert A. Montgomery, M.D., D. Phil., a professor of surgery at the Johns Hopkins University School of Medicine and leader of the study, was quoted saying.

Dr. Montgomery believes that the widespread use of a pre-surgery protocol developed at Johns Hopkins, which removes problematic antibodies from a patient’s blood prior to transplant, could lead to potentially 3,000 more kidney transplants from living donors each year. The pre-surgery process cannot be used at this point with patients receiving cadaver organs because several days of treatment are needed before surgery can take place.

“We have this pre-surgery therapy that doubles a person’s survival rate. If this were a cancer drug that doubled chances of survival, people would be lined up out the door to get it. It’s really extraordinary to go from 30 percent survival to 80 percent survival after eight years,” Dr. Montgomery said.

The new protocol removes the problem antibodies from the blood before the transplant takes place through plasmapheresis, a process that removes, filters, and replaces a patient’s plasma supply. Then, the patient receives low-dose intravenous immune globulin (IVIg), which intends to replace those problematic antibodies and prevent their return. This process, which conditions the body to accept the new organ, is performed every other day for several days before transplant and then for up to 10 days following the surgery.

HLA-sensitized patients have been very difficult to match with fewer than 7 percent receiving transplants each year compared to a 98 percent transplant rate among patients offered the Johns Hopkins’ plasmapheresis protocol.
“The protocol essentially allows an incompatible kidney to function long term, and in the majority of patients, the harmful antibodies do not return. Some other hospitals have begun using it, as well, but many others were awaiting data indicating long-term benefit to patients,” Dr. Montgomery said.

“Now we have it, the first study to show long-term survival benefit from desensitization,” he says.
In the new research, the team transplanted 211 HLA-sensitized patients between February 1998 and December 2009 using plasmapheresis and IVIg before and after surgery. On the day each patient received his or her incompatible transplant, researchers identified five patients on the kidney waiting list who most closely matched the characteristics of the person who got the new organ. The researchers then followed the progress of those transplant candidates, as well, whether they remained on dialysis or eventually got a compatible organ.

After the first year, each group of patients had about the same chance for survival, in the low 90 percentile range. After eight years, however, the treatment group had an 80.6 percent survival rate, while the dialysis group had a 30.5 percent chance of survival. The patients who waited on the list with the possibility of receiving a compatible kidney had a 49.1 percent chance of eight-year survival.
In 2008, of the 82,000 patients on the waiting list in the United States, 16,520 received kidney transplants whereas 4,800 died waiting for one.

“This treatment increases survival, ensures a better lifestyle and saves the health care system money. There aren’t many things like that,” Dr. Montgomery said. He believes these findings will ease doubts about the ability of HLA-sensitized candidates to have successful transplants.

SOURCE: New England Journal of Medicine, July 27, 2011




comments powered by Disqus